Trial Profile
A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Sep 2022
Price :
$35
*
At a glance
- Drugs Cannabidiol (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Botanix Pharmaceuticals
- 30 Mar 2020 Status changed from recruiting to completed.
- 01 Aug 2019 According to a Botanix Pharmaceuticals media release, enrolment expected to complete in 4Q CY2019.
- 16 May 2019 Planned primary completion date changed from 26 Mar 2020 to 20 Feb 2020.